Intrinsic value of PerkinElmer - PKI

Previous Close

$81.20

  Intrinsic Value

$56.62

stock screener

  Rating & Target

sell

-30%

Previous close

$81.20

 
Intrinsic value

$56.62

 
Up/down potential

-30%

 
Rating

sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of PKI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2017(a)
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  0.52
  7.80
  7.52
  7.27
  7.04
  6.84
  6.65
  6.49
  6.34
  6.21
  6.08
  5.98
  5.88
  5.79
  5.71
  5.64
  5.58
  5.52
  5.47
  5.42
  5.38
  5.34
  5.31
  5.28
  5.25
  5.22
  5.20
  5.18
  5.16
  5.15
  5.13
Revenue, $m
  2,116
  2,281
  2,453
  2,631
  2,816
  3,009
  3,209
  3,417
  3,634
  3,859
  4,094
  4,339
  4,594
  4,860
  5,137
  5,427
  5,730
  6,046
  6,376
  6,722
  7,083
  7,462
  7,858
  8,272
  8,706
  9,161
  9,638
  10,137
  10,660
  11,209
  11,784
Variable operating expenses, $m
 
  1,992
  2,125
  2,263
  2,407
  2,556
  2,711
  2,872
  3,040
  3,215
  3,397
  3,361
  3,559
  3,765
  3,980
  4,205
  4,439
  4,684
  4,940
  5,208
  5,488
  5,781
  6,088
  6,409
  6,745
  7,098
  7,467
  7,854
  8,259
  8,684
  9,130
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  1,832
  1,992
  2,125
  2,263
  2,407
  2,556
  2,711
  2,872
  3,040
  3,215
  3,397
  3,361
  3,559
  3,765
  3,980
  4,205
  4,439
  4,684
  4,940
  5,208
  5,488
  5,781
  6,088
  6,409
  6,745
  7,098
  7,467
  7,854
  8,259
  8,684
  9,130
Operating income, $m
  283
  289
  328
  368
  409
  453
  498
  545
  594
  644
  697
  977
  1,035
  1,095
  1,157
  1,222
  1,291
  1,362
  1,436
  1,514
  1,595
  1,681
  1,770
  1,863
  1,961
  2,063
  2,171
  2,283
  2,401
  2,525
  2,654
EBITDA, $m
  383
  536
  577
  619
  662
  707
  754
  803
  854
  907
  963
  1,020
  1,080
  1,143
  1,208
  1,276
  1,347
  1,422
  1,499
  1,581
  1,666
  1,754
  1,848
  1,945
  2,047
  2,154
  2,266
  2,384
  2,507
  2,636
  2,771
Interest expense (income), $m
  31
  37
  42
  48
  55
  61
  68
  75
  82
  90
  98
  106
  115
  124
  133
  143
  153
  164
  175
  186
  198
  211
  224
  238
  253
  268
  284
  301
  318
  337
  356
Earnings before tax, $m
  244
  252
  285
  319
  355
  392
  430
  470
  511
  554
  599
  871
  920
  971
  1,024
  1,080
  1,138
  1,198
  1,261
  1,328
  1,397
  1,470
  1,545
  1,625
  1,708
  1,795
  1,887
  1,982
  2,083
  2,188
  2,298
Tax expense, $m
  28
  68
  77
  86
  96
  106
  116
  127
  138
  150
  162
  235
  248
  262
  276
  291
  307
  324
  341
  358
  377
  397
  417
  439
  461
  485
  509
  535
  562
  591
  621
Net income, $m
  234
  184
  208
  233
  259
  286
  314
  343
  373
  405
  438
  636
  672
  709
  748
  788
  830
  875
  921
  969
  1,020
  1,073
  1,128
  1,186
  1,247
  1,311
  1,377
  1,447
  1,520
  1,597
  1,678

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  359
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  4,277
  4,224
  4,542
  4,872
  5,215
  5,572
  5,942
  6,328
  6,729
  7,146
  7,581
  8,034
  8,507
  8,999
  9,513
  10,050
  10,610
  11,196
  11,808
  12,448
  13,117
  13,818
  14,551
  15,319
  16,123
  16,965
  17,847
  18,772
  19,741
  20,757
  21,822
Adjusted assets (=assets-cash), $m
  3,918
  4,224
  4,542
  4,872
  5,215
  5,572
  5,942
  6,328
  6,729
  7,146
  7,581
  8,034
  8,507
  8,999
  9,513
  10,050
  10,610
  11,196
  11,808
  12,448
  13,117
  13,818
  14,551
  15,319
  16,123
  16,965
  17,847
  18,772
  19,741
  20,757
  21,822
Revenue / Adjusted assets
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
  0.540
Average production assets, $m
  595
  641
  689
  739
  791
  845
  902
  960
  1,021
  1,084
  1,150
  1,219
  1,291
  1,366
  1,444
  1,525
  1,610
  1,699
  1,792
  1,889
  1,990
  2,097
  2,208
  2,324
  2,446
  2,574
  2,708
  2,848
  2,996
  3,150
  3,311
Working capital, $m
  587
  246
  265
  284
  304
  325
  347
  369
  392
  417
  442
  469
  496
  525
  555
  586
  619
  653
  689
  726
  765
  806
  849
  893
  940
  989
  1,041
  1,095
  1,151
  1,211
  1,273
Total debt, $m
  1,046
  1,212
  1,385
  1,564
  1,750
  1,943
  2,144
  2,353
  2,570
  2,796
  3,032
  3,278
  3,534
  3,801
  4,079
  4,370
  4,674
  4,991
  5,323
  5,670
  6,033
  6,412
  6,810
  7,226
  7,662
  8,118
  8,596
  9,097
  9,623
  10,173
  10,751
Total liabilities, $m
  2,123
  2,289
  2,462
  2,641
  2,827
  3,020
  3,221
  3,430
  3,647
  3,873
  4,109
  4,355
  4,611
  4,878
  5,156
  5,447
  5,751
  6,068
  6,400
  6,747
  7,110
  7,489
  7,887
  8,303
  8,739
  9,195
  9,673
  10,174
  10,700
  11,250
  11,828
Total equity, $m
  2,154
  1,935
  2,080
  2,231
  2,388
  2,552
  2,722
  2,898
  3,082
  3,273
  3,472
  3,680
  3,896
  4,122
  4,357
  4,603
  4,860
  5,128
  5,408
  5,701
  6,008
  6,329
  6,664
  7,016
  7,384
  7,770
  8,174
  8,598
  9,041
  9,507
  9,995
Total liabilities and equity, $m
  4,277
  4,224
  4,542
  4,872
  5,215
  5,572
  5,943
  6,328
  6,729
  7,146
  7,581
  8,035
  8,507
  9,000
  9,513
  10,050
  10,611
  11,196
  11,808
  12,448
  13,118
  13,818
  14,551
  15,319
  16,123
  16,965
  17,847
  18,772
  19,741
  20,757
  21,823
Debt-to-equity ratio
  0.486
  0.630
  0.670
  0.700
  0.730
  0.760
  0.790
  0.810
  0.830
  0.850
  0.870
  0.890
  0.910
  0.920
  0.940
  0.950
  0.960
  0.970
  0.980
  0.990
  1.000
  1.010
  1.020
  1.030
  1.040
  1.040
  1.050
  1.060
  1.060
  1.070
  1.080
Adjusted equity ratio
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458
  0.458

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  234
  184
  208
  233
  259
  286
  314
  343
  373
  405
  438
  636
  672
  709
  748
  788
  830
  875
  921
  969
  1,020
  1,073
  1,128
  1,186
  1,247
  1,311
  1,377
  1,447
  1,520
  1,597
  1,678
Depreciation, amort., depletion, $m
  100
  247
  249
  251
  253
  255
  257
  259
  261
  263
  265
  43
  45
  48
  51
  54
  57
  60
  63
  67
  70
  74
  78
  82
  86
  91
  95
  100
  105
  111
  117
Funds from operations, $m
  316
  432
  457
  484
  512
  540
  570
  602
  634
  668
  703
  679
  717
  757
  798
  842
  887
  934
  984
  1,036
  1,090
  1,147
  1,206
  1,268
  1,333
  1,401
  1,473
  1,547
  1,626
  1,708
  1,794
Change in working capital, $m
  -35
  18
  19
  19
  20
  21
  22
  22
  23
  24
  25
  26
  28
  29
  30
  31
  33
  34
  36
  37
  39
  41
  43
  45
  47
  49
  51
  54
  57
  59
  62
Cash from operations, $m
  351
  414
  439
  465
  492
  520
  549
  579
  611
  643
  678
  652
  689
  728
  768
  810
  854
  900
  948
  998
  1,051
  1,106
  1,163
  1,223
  1,286
  1,352
  1,421
  1,493
  1,569
  1,649
  1,732
Maintenance CAPEX, $m
  0
  -21
  -23
  -24
  -26
  -28
  -30
  -32
  -34
  -36
  -38
  -41
  -43
  -45
  -48
  -51
  -54
  -57
  -60
  -63
  -67
  -70
  -74
  -78
  -82
  -86
  -91
  -95
  -100
  -105
  -111
New CAPEX, $m
  -32
  -46
  -48
  -50
  -52
  -54
  -56
  -59
  -61
  -63
  -66
  -69
  -72
  -75
  -78
  -81
  -85
  -89
  -93
  -97
  -102
  -106
  -111
  -116
  -122
  -128
  -134
  -140
  -147
  -154
  -162
Cash from investing activities, $m
  -101
  -67
  -71
  -74
  -78
  -82
  -86
  -91
  -95
  -99
  -104
  -110
  -115
  -120
  -126
  -132
  -139
  -146
  -153
  -160
  -169
  -176
  -185
  -194
  -204
  -214
  -225
  -235
  -247
  -259
  -273
Free cash flow, $m
  250
  347
  368
  390
  414
  438
  463
  489
  516
  544
  573
  543
  575
  608
  642
  678
  716
  755
  796
  838
  883
  929
  978
  1,029
  1,082
  1,138
  1,197
  1,258
  1,322
  1,389
  1,460
Issuance/(repayment) of debt, $m
  63
  167
  172
  179
  186
  193
  201
  209
  217
  226
  236
  246
  256
  267
  279
  291
  304
  317
  332
  347
  363
  380
  397
  416
  436
  456
  478
  501
  525
  551
  577
Issuance/(repurchase) of shares, $m
  -137
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -84
  167
  172
  179
  186
  193
  201
  209
  217
  226
  236
  246
  256
  267
  279
  291
  304
  317
  332
  347
  363
  380
  397
  416
  436
  456
  478
  501
  525
  551
  577
Total cash flow (excl. dividends), $m
  152
  514
  540
  569
  599
  631
  664
  698
  733
  770
  809
  789
  831
  875
  921
  969
  1,019
  1,072
  1,127
  1,185
  1,246
  1,309
  1,375
  1,445
  1,518
  1,595
  1,675
  1,759
  1,847
  1,940
  2,037
Retained Cash Flow (-), $m
  -44
  -139
  -145
  -151
  -157
  -163
  -170
  -177
  -184
  -191
  -199
  -208
  -216
  -226
  -235
  -246
  -257
  -268
  -280
  -293
  -307
  -321
  -336
  -352
  -368
  -386
  -404
  -423
  -444
  -465
  -488
Prev. year cash balance distribution, $m
 
  358
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  734
  395
  418
  442
  468
  494
  521
  550
  579
  610
  581
  615
  649
  686
  723
  763
  804
  847
  892
  939
  988
  1,040
  1,093
  1,150
  1,209
  1,271
  1,335
  1,403
  1,474
  1,549
Discount rate, %
 
  4.40
  4.62
  4.85
  5.09
  5.35
  5.62
  5.90
  6.19
  6.50
  6.83
  7.17
  7.53
  7.90
  8.30
  8.71
  9.15
  9.60
  10.08
  10.59
  11.12
  11.67
  12.26
  12.87
  13.51
  14.19
  14.90
  15.64
  16.43
  17.25
  18.11
PV of cash for distribution, $m
 
  703
  361
  363
  363
  360
  356
  349
  340
  329
  315
  271
  257
  242
  225
  207
  188
  169
  150
  132
  114
  97
  82
  68
  55
  44
  34
  26
  20
  15
  11
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.

FINANCIAL RATIOS  of  PerkinElmer (PKI)

Valuation Ratios
P/E Ratio 38
Price to Sales 4.2
Price to Book 4.1
Price to Tangible Book
Price to Cash Flow 25.4
Price to Free Cash Flow 27.9
Growth Rates
Sales Growth Rate 0.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 14.3%
Cap. Spend. - 3 Yr. Gr. Rate -3.9%
Financial Strength
Quick Ratio 359
Current Ratio 0.3
LT Debt to Equity 48.5%
Total Debt to Equity 48.6%
Interest Coverage 9
Management Effectiveness
Return On Assets 6.2%
Ret/ On Assets - 3 Yr. Avg. 5.5%
Return On Total Capital 7.4%
Ret/ On T. Cap. - 3 Yr. Avg. 6.5%
Return On Equity 11%
Return On Equity - 3 Yr. Avg. 9.7%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 47.9%
Gross Margin - 3 Yr. Avg. 46.2%
EBITDA Margin 17.7%
EBITDA Margin - 3 Yr. Avg. 16%
Operating Margin 13.4%
Oper. Margin - 3 Yr. Avg. 11.6%
Pre-Tax Margin 11.5%
Pre-Tax Margin - 3 Yr. Avg. 9.7%
Net Profit Margin 11.1%
Net Profit Margin - 3 Yr. Avg. 9.4%
Effective Tax Rate 11.5%
Eff/ Tax Rate - 3 Yr. Avg. 8.8%
Payout Ratio 13.2%

PKI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the PKI stock intrinsic value calculation we used $2116 million for the last fiscal year's total revenue generated by PerkinElmer. The default revenue input number comes from 2017 income statement of PerkinElmer. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our PKI stock valuation model: a) initial revenue growth rate of 7.8% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.4%, whose default value for PKI is calculated based on our internal credit rating of PerkinElmer, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of PerkinElmer.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of PKI stock the variable cost ratio is equal to 88.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for PKI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for PerkinElmer.

Corporate tax rate of 27% is the nominal tax rate for PerkinElmer. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the PKI stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for PKI are equal to 28.1%.

Life of production assets of 28.4 years is the average useful life of capital assets used in PerkinElmer operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for PKI is equal to 10.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2154 million for PerkinElmer - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 110.64 million for PerkinElmer is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of PerkinElmer at the current share price and the inputted number of shares is $9.0 billion.

RELATED COMPANIES Price Int.Val. Rating
TMO Thermo Fisher 215.32 70.89  str.sell
HBIO Harvard Biosci 3.90 0.25  str.sell
BRKR Bruker 35.07 21.02  sell
WAT Waters 214.77 70.73  str.sell
A Agilent Techno 73.48 82.94  buy
BIO Bio-Rad Labora 254.65 56.94  str.sell
MTD Mettler-Toledo 670.88 301.62  str.sell

COMPANY NEWS

▶ PerkinElmer Completes Acquisition of EUROIMMUN   [Dec-19-17 04:15PM  Business Wire]
▶ PerkinElmer to Present at Citi Global Healthcare Conference   [Nov-21-17 04:15PM  Business Wire]
▶ Perkinelmer Earns Relative Strength Rating Upgrade; Hits Key Threshold   [Nov-08-17 03:00AM  Investor's Business Daily]
▶ PerkinElmer beats Street 3Q forecasts   [04:38PM  Associated Press]
▶ PerkinElmer Elects Pascale Witz to its Board of Directors   [Oct-30-17 04:15PM  Business Wire]
▶ PerkinElmer Board Declares Quarterly Dividend   [Oct-27-17 04:15PM  Business Wire]
▶ PerkinElmer meets 2Q profit forecasts   [Aug-03-17 05:39PM  Associated Press]
▶ PerkinElmer Board Declares Quarterly Dividend   [Jul-24-17 04:15PM  Business Wire]
▶ What Happened in the Stock Market Today   [Jun-19-17 05:03PM  Motley Fool]
▶ The Hot Stock: PerkinElmer Soars 6.5%   [04:15PM  Barrons.com]
▶ Picks of Steel   [02:15PM  CNBC Videos]
▶ Story Stocks from Briefing.com   [10:16AM  Briefing.com]
▶ PerkinElmer beats Street 1Q forecasts   [04:38PM  Associated Press]
▶ PerkinElmer Takes Cautious Approach to M&A   [Apr-30-17 03:40PM  TheStreet.com]
▶ PerkinElmer Board Declares Quarterly Dividend   [Apr-28-17 04:15PM  Business Wire]
▶ PerkinElmer to Hold Earnings Call on Thursday, May 4, 2017   [Apr-07-17 04:15PM  Business Wire]
Financial statements of PKI
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.